SCHEMBL19512592

SCHEMBL19512592

COc1ccc(CN(CC(=O)NO)Cc2ccc(OC)cc2)cc1

nearest known ligand 0.72

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ MEP1B Q16820 14/20 0.72
▸ MEP1A Q16819 1/20 0.72
▸ BMP1 P13497 2/20 0.54
▸ HTT P42858 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19474733 0.94 MEP1B (0.66) MEP1BMEP1ABMP1
SCHEMBL19474713 0.93 MEP1B (0.65) MEP1BMEP1ABMP1
SCHEMBL19510229 0.93 MEP1B (0.65) MEP1BMEP1ABMP1
SCHEMBL31260532 0.89 MEP1B (0.78) MEP1BMEP1A
SCHEMBL19510228 0.89 MEP1B (0.78) MEP1BMEP1A
SCHEMBL19474721 0.85 MEP1B (0.69) MEP1BMEP1A
SCHEMBL19512317 0.85 MEP1B (1.00) MEP1BMEP1A
SCHEMBL31260457 0.85 MEP1B (1.00) MEP1BMEP1A
SCHEMBL20952391 0.84 MEP1B (0.73) MEP1BMEP1ABMP1
SCHEMBL23892089 0.84 MEP1B (0.71) MEP1BMEP1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12378186-B2 Inhibitors of meprin α and β VIVORYON THERAPEUTICS N.V. (DE) 2025-08-05 — — US disclosed
CN-114507175-B Novel inhibitors of hypnotins alpha and beta 维沃里翁治疗股份有限公司 2024-10-01 — — CN disclosed
CN-114507175-A Novel inhibitors of hypnotic proteins alpha and beta 维沃里翁治疗股份有限公司 2022-05-17 — — CN disclosed
EP-3967679-A1 NOVEL INHIBITORS OF MEPRIN ALPHA AND BETA Vivoryon Therapeutics AG (DE) 2022-03-16 — — EP disclosed
CN-109195947-B Novel inhibitors of hypnotic proteins alpha and beta 维沃里翁治疗股份有限公司 2022-03-04 — — CN disclosed
EP-3445744-B1 NOVEL INHIBITORS OF MEPRIN ALPHA AND BETA VIVORYON THERAPEUTICS AG (DE) 2021-10-06 — — EP disclosed
EP-3445744-B1 NOVEL INHIBITORS OF MEPRIN ALPHA AND BETA VIVORYON THERAPEUTICS AG (DE) 2021-10-06 — — EP disclosed
US-10975019-B2 Inhibitors of meprin α and β VIVORYON THERAPEUTICS AG (DE) 2021-04-13 — — US disclosed
US-10975019-B2 Inhibitors of meprin α and β VIVORYON THERAPEUTICS AG (DE) 2021-04-13 — — US disclosed
US-20190127317-A1 NOVEL INHIBITORS OF MEPRIN ALPHA AND BETA VIVORYON THERAPEUTICS N.V (DE) 2019-05-02 — — US disclosed
US-20190127317-A1 NOVEL INHIBITORS OF MEPRIN ALPHA AND BETA VIVORYON THERAPEUTICS N.V (DE) 2019-05-02 — — US disclosed
WO-2017182433-A1 NOVEL INHIBITORS OF MEPRIN ALPHA AND BETA Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) 2017-10-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190127317-A1 NOVEL INHIBITORS OF MEPRIN ALPHA AND BETA MEP1A, MEP1B, CAPRIN1 MEP1B 2/4885MEP1A 1/4885BMP1 397/4885
US-12378186-B2 Inhibitors of meprin α and β MEP1A, MEP1B, CAPRIN1 MEP1B 2/4885MEP1A 1/4885BMP1 249/4885
US-10975019-B2 Inhibitors of meprin α and β MEP1A, MEP1B, CAPRIN1 MEP1B 2/4885MEP1A 1/4885BMP1 249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback